Our innovative processes include protocol design, site training, and real time data quality analysis

Clinical understanding of neurobiology is incomplete, contributing to clinical development programs in Central Nervous System (CNS) having the highest failure rates across all therapeutic areas. CNS clinical trials bring specific challenges including managing placebo response, incorporating soft endpoints, and a particular focus on reducing patient burden.

Unsurprisingly this had led to a challenging of accepted and established norms by CNS drug developers.

We support sponsors in minimising development risk and maximising probability of success through:

  • Access to the latest, applied technology innovation and processes
  • Working with our highly qualified and therapeutically trained staff
  • Real time data quality monitoring and analysis

ICON's experienced neuroscience and drug development teams work across all areas of CNS research including:

ICON CNS experience in last five years

  • 157

    Studies conducted

  • 42,000

    Patients involved

  • 5,700

    Sites worldwide

Services for CNS, Pain and Ageing Diseases

Our Protocol Optimisation and Clinical Development Plans service is complemented with Adaptive Design competency and regulatory approved software. Our full service study/program implementation and execution includes: 

Dedicated specialist teams

All staff assigned to projects including; Project Management, Drug Development, Site Identification and Feasibility, and Medical oversight attend customised training programs. Over the past 5 years ICON have conducted phase II & III studies in a range of CNS indications. We also offer dedicated teams for rare and paediatric CNS programs.

File Thumbnail

Traumatic Brain Injury: From identifying biomarkers to improving clinical trial efficiency

This whitepaper explores the impact of TBI on different populations as well as challenges and opportunities in clinical research.

File Thumbnail

Whitepaper: Key considerations for trials in chronic pain

The opioid crisis has created an urgent need for innovative pain medications without the use of opioids. Unfortunately, clinical development of non-opioid pain medications, such as non-steroidal anti-inflammatory drugs (NSAIDS), has been hindered by a massive placebo-response. In this whitepaper, we discuss the aspects of pain studies that sponsors will need to consider to ensure success of their chronic pain trial model.

File Thumbnail

Whitepaper: Key considerations for Parkinson’s disease trials

Download the whitepaper